Insights

Strategic expansion Skye Bioscience is pursuing a major strategic move by agreeing to acquire Redx Pharma, signaling a growth trajectory through expanded oncology and fibrotic disease pipelines. This presents cross-sell opportunities to Redx's existing partners and potential for expanded collaboration with pharma companies seeking integrated metabolic and cancer/fibrotic therapeutics.

Metabolic obesity focus With nimacimab advancing to a Phase 2 trial in obesity and a combination strategy with a GLP-1R agonist, there is a clear opportunity to engage investors and pharma collaborators interested in obesity pathways, CB1 modulation, and peripherally restricted therapies that may differentiate from central CB1 approaches.

Delivery partnerships Halozyme partnership to develop higher-dose subcutaneous nimacimab highlights a potential channel for scalable delivery solutions. This opens doors to discussions with contract manufacturing and drug-delivery specialists to support commercial-scale dosing regimens and broaden market access.

Financial and investor signals Significant funding and a financing commitment for the Redx deal, alongside ongoing litigation risk from a class-action suit, indicate active investor interest yet necessitate clear value storytelling. This creates opportunity to offer strategic advisory, investor relations support, and data packages to bolster credibility with stakeholders.

Clinical and visibility leverage Upcoming presentations at GLP-1 Based Therapeutics Summit and preclinical data showcases provide timely opportunities to coordinate co-promotional events, publications, and investigator-initiated trial (IIT) partnerships. Leverage these milestones to engage potential collaborators, contract research organizations, and clinical trial sites.

Similar companies to Skye Bioscience Inc.

Skye Bioscience Inc. Tech Stack

Skye Bioscience Inc. uses 8 technology products and services including Sage Intacct, Taboola, Amazon Web Services, and more. Explore Skye Bioscience Inc.'s tech stack below.

Media & News

Skye Bioscience Inc.'s Email Address Formats

Skye Bioscience Inc. uses at least 3 email formats:
Skye Bioscience Inc. Email FormatsExamplePercentage
FL@skyebioscience.comJD@skyebioscience.com
71%
FLast@skyebioscience.comJDoe@skyebioscience.com
19%
LF@skyebioscience.comDJ@skyebioscience.com
10%

Frequently Asked Questions

What is Skye Bioscience Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Skye Bioscience Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Skye Bioscience Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Skye Bioscience Inc.'s official website is skyebioscience.com and has social profiles on LinkedIn.

How much revenue does Skye Bioscience Inc. generate?

Minus sign iconPlus sign icon
As of November 2026, Skye Bioscience Inc.'s annual revenue is estimated to be <$1M.

What is Skye Bioscience Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Skye Bioscience Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Skye Bioscience Inc. have currently?

Minus sign iconPlus sign icon
As of November 2026, Skye Bioscience Inc. has approximately 17 employees across 2 continents, including North America and Europe. Key team members include Vp Corporate Development & Investor Relations: K. T., Non Executive Director: A. J. O. and Director: M. D. Explore Skye Bioscience Inc.'s employee directory with LeadIQ.

What industry does Skye Bioscience Inc. belong to?

Minus sign iconPlus sign icon
Skye Bioscience Inc. operates in the Biotechnology Research industry.

What technology does Skye Bioscience Inc. use?

Minus sign iconPlus sign icon
Skye Bioscience Inc.'s tech stack includes Sage Intacct, Taboola, Amazon Web Services, WordPress, Shopify, Microsoft 365, Vimeo and Adobe Creative Suite.

What is Skye Bioscience Inc.'s email format?

Minus sign iconPlus sign icon
Skye Bioscience Inc.'s email format typically follows the pattern of FL@skyebioscience.com. Find more Skye Bioscience Inc. email formats with LeadIQ.

How much funding has Skye Bioscience Inc. raised to date?

Minus sign iconPlus sign icon
As of November 2026, Skye Bioscience Inc. has raised $111M in funding. The last funding round occurred on Jan 29, 2024.

When was Skye Bioscience Inc. founded?

Minus sign iconPlus sign icon
Skye Bioscience Inc. was founded in 2011.
Skye Bioscience Inc. logo

Skye Bioscience Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Skye Bioscience Inc. is a biotechnology research company focused on metabolic health, developing new molecules that modulate G-protein coupled receptors. The firm aims to deliver first-in-class therapies with distinct clinical and potential commercial advantages by pursuing biologic targets supported by human proof of mechanism. Based in San Diego, California, the company operates with a relatively small to mid-sized team and concentrates on obesity and related metabolic disorders.

Its lead candidate nimacimab is a peripherally restricted antibody that inhibits CB1, and the company planned to initiate a Phase 2 trial in obesity in the third quarter of 2024, comparing monotherapy with a combination approach involving Wegovy, a GLP-1 receptor agonist. In January 2026 Skye announced a collaboration with Halozyme Therapeutics to explore higher-dose subcutaneous administration strategies for nimacimab.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2011
Employees
11-50

Section iconFunding & Financials

  • $111M

    Skye Bioscience Inc. has raised a total of $111M of funding over 10 rounds. Their latest funding round was raised on Jan 29, 2024 as a Post IPO Equity.

  • <$1M

    Skye Bioscience Inc.'s revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.